
We claim:

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salts, derivatives, pro-drugs, stereoisomer's, solvates or biologically active metabolites thereof;

wherein;

R_1 is selected from an optionally substituted alkyl, amino, cycloalkyl, aryl, heterocyclyl, heteroaryl, heterocyclylalkyl or heteroarylalkyl;

R_2 is hydrogen; or

R_1 and R_2 may be taken together with the atoms to which they are attached to form an optionally substituted 4-7 membered ring containing 0-3 additional hetero atoms independently selected from N, O and S in any stable combination;

R_3 is selected from hydrogen, carboxy, optionally substituted alkyl or heterocyclylalkyl; or

R_1 and R_3 may be taken together with the carbon atoms to which they are attached to form an optionally substituted 6-8 membered ring containing 0-3 additional hetero atoms independently selected from N, O and S in any stable combination; wherein the optional substituent, at each occurrence, is independently selected from one or more R_6;

L is a linker selected from $-CH_2-CH_2-$, -CH=CH- or $-CH_2-S-$;

R_4 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted amino, optionally substituted aryl, $B(OH)_2$, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally

substituted heteroarylalkyl, optionally substituted heterocyclylalkyl, wherein the optional substituent, in each occurrence, is independently selected from one or more R_7;

R_5 is hydrogen; or

R_4 and R_5 may be taken together with the carbon atoms to which they are attached to form an optionally substituted 5-8 membered ring optionally containing 0-4 hetero atoms independently selected from N, O and S in any stable combination; wherein the optional substituent, at each occurrence, is independently selected from alkoxy, halo, hydroxyl, an optionally substituted alkyl or an optionally substituted alkenyl;

R_6 is independently selected from optionally substituted alkyl, optionally substituted heterocyclylalkyl, $-COOR_8$ or two of the R_6 groups on the same atom combined together to form an optionally substituted spiro condensed 3-8 membered ring containing 0-3 hetero atoms independently selected from N, O and S; wherein the optional substituent is independently selected from one or more R_8, $-(CH_2)_{1-3}OR_8$, $-COOR_8$, $-COR_8$, $-COCH_2OR_8$, $-CONR_8R_8$, $-NR_8R_8$ or an optionally substituted heterocyclyl;

R_7 is independently selected from cyano, nitro, halogen, $-OR_8$, $-NR_8R_8$, $-COOR_8$, $-CONR_8R_8$, $-NR_8COR_8$, haloalkyl, haloalkoxy, $-NHC(=NR_9)NHR_9$, $-(CH_2)_{1-3}OR_8$, $-C(=NOH)NH_2$ or optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryloxy, cyanoalkyl, cyanoalkoxy, cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl or optionally substituted heterocyclylalkyl;

R_8 at each occurrence is independently selected from hydrogen or optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, $-CH_2C(=NOH)NH_2$ or two of the R_8 groups on the same atom can be taken together with the atom to which they are attached to form an optionally substituted 3-8 membered ring containing 0-3 hetero atoms independently selected from N, O and S in any stable combination; wherein the optional substituent is independently selected from $-COOC_1$-C_4alkyl, halogen, hydroxy, cyano, alkyl, alkoxy, nitro or haloalkoxy;

R_9 ateach occurrence is independently selected from hydrogen or $-COOC_1$-C_4alkyl.

2. The compound of claim 1, wherein linker L is –CH=CH-.

3. The compound of claim 1, wherein R_1 is C_1-C_4alkyl or heterocyclylalkyl.

4. The compound of claim 1, wherein R_1 and R_3 can be taken together with the carbon atoms to which they are attached to form a 6-membered ring optionally substituted with one or more R_6.


5. The compound of claim 1, wherein R_1 and R_3 can be taken together with the carbon atoms to which they are attached to form a 7-membered ring containing one additional N atom and optionally substituted with one or more R_6.

6. The compound of claim 4 or 5, wherein R_6 is alkyl, heterocyclylalkyl or $-COOR_8$ wherein R_8 is C_{1-4} alkyl.

7. The compound of claim 4 or 5, wherein two of the R_6 groups on the same atom combined together to form an optionally substituted spiro condensed 3-8 membered ring containing 0-3 hetero atoms independently selected from N, O and S; wherein the optional substituent is independently selected from alkyl, $-(CH_2)_{1-3}OR_8$, $-COOR_8$, $-COR_8$, $-COCH_2OR_8$, $-CONR_8R_8$, $-NR_8R_8$ or an optionally substituted heterocyclyl.

8. The compound of claim 1, wherein R_4 is aryl, arylalkyl, heteroaryl, or heteroarylalkyl which may be optionally substituted with R_7.


9. The compound of claim 1 wherein the compound of formula (I) is a compound of Formula (IA)



(IA)

wherein L, R_4 and R_5 are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 wherein the compound of formula (I) is a compound of Formula (IB)




(IB)

wherein

R_{10} is selected from optionally substituted alkyl,-$(CH_2)_{1-3}OR_8$,-COR_8, -$COCH_2OR_8$ or -$CONR_8R_8$; and

L, R_4, R_5 and R_8 are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 wherein the compound of formula (I) is a compound of Formula (IC)




(IC)

wherein

R_{11} is selected from hydrogen, optionally substituted alkyl, heterocyclylalkyl or -$COOR_8$; and

L, R_4, R_5 and R_8 are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 wherein the compound of formula (I) is a compound of Formula (ID)



(ID)

wherein L, R_4 and R_5 are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

13. A compound selected from the group consisting of

Comp. No	Compound Name
1.	(E)-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-

Comp. No	Compound Name
	tetrahydropyridin-4-yl)boronic acid;
2.	(E)-6-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
3.	(E)-6-(3-(4-(3-methylbenzofuran-2-yl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
4.	(E)-6-(3-(5,6-dihydro-[4,4'-bipyridin]-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
5.	(E)-6-(3-(5',6'-dihydro-[3,4'-bipyridin]-1'(2'H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
6.	(E)-6-(3-oxo-3-(4-(pyrimidin-2-yl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
7.	(E)-6-(3-oxo-3-(4-(pyrimidin-5-yl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
8.	(E)-6-(3-(4-(4-fluorophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
9.	(E)-6-(3-(4-(4-hydroxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
10.	(E)-6-(3-(4-(3-hydroxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
11.	(E)-6-(3-(4-(2-hydroxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
12.	(E)-6-(3-(4-(4-methoxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-dihydro-1,8-naphthyridin-2(1H)-one;

Comp. No	Compound Name
13.	(E)-6-(3-(4-(3-methoxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
14.	(E)-6-(3-(4-(2-methoxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
15.	(E)-6-(3-oxo-3-(4-(4-(trifluoromethoxy)phenyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
16.	(E)-6-(3-oxo-3-(4-(p-tolyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
17.	(E)-3-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile;
18.	(E)-4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile;
19.	(Z)-N'-hydroxy-4-(1-((E)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzimidamide;
20.	(E)-6-(3-(4-(4-nitrophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
21.	(E)-6-(3-(4-(4-aminophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
22.	(E)-N-(4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)acetamide;
23.	(E)-6-(3-(4-(3-nitrophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
24.	(E)-6-(3-(4-(3-aminophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-

Comp. No	Compound Name
	1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
25.	(E)-N-(3-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)acetamide;
26.	(E)-ethyl4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzoate;
27.	(E)-4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzoic acid;
28.	(E)-4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzamide;
29.	(E)-di-tert-butoxycarbonyl-1-(4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)guanidine;
30.	(E)-1-(4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)guanidine trifluoro aceticacid;
31.	(E)-1-(3-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)guanidine;
32.	(E)-2-(4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)acetonitrile;
33.	(Z)-N'-hydroxy-2-(4-(1-((E)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)acetimidamide;
34.	(E)-4-((4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)methyl)benzonitrile;
35.	(E)-4-((4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzyl)oxy)benzonitrile;

Comp. No	Compound Name
36.	(E)-6-(3-(4-(3-(morpholinomethyl)phenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
37.	(E)-6-(3-(4-(3,5-dihydroxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
38.	(E)-6-(3-(4-(3,4-dichlorophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
39.	(E)-6-(3-(4-(2-methyl-3-nitrophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
40.	(E)-6-(3-(4-(3-amino-2-methylphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
41.	(E)-N-(2-methyl-3-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)acetamide;
42.	(E)-6-(3-(4-(6-methoxynaphthalen-2-yl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
43.	(E)-6-(3-oxo-3-(4-(thiophen-2-yl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
44.	(E)-6-(3-oxo-3-(4-(thiazol-2-yl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
45.	(E)-6-(3-(4-(1-methyl-1H-imidazol-2-yl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
46.	(E)-6-(3-(4-(1-methyl-1H-pyrazol-4-yl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
47.	(E)-2-(4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-

Comp. No	Compound Name
	1,2,3,6-tetrahydropyridin-4-yl)benzyl)isoindoline-1,3-dione;
48.	(E)-2-(3-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzyl)isoindoline-1,3-dione;
49.	6-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)propyl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
50.	6-((2-oxo-2-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)ethyl)thio)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
51.	(E)-tert-butyl 2-oxo-6-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxylate;
52.	(E)-6-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro [[1,8] naph thyridine-3,4'-piperidin]-2(4H)-one trifluoro acetic acid;
53.	(E)-3-(2-morpholinoethyl)-6-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one;
54.	(E)-7-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one trifluoroacetic acid;
55.	(E)-4-methyl-7-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;
56.	(E)-4-(2-morpholinoethyl)-7-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;
57.	(E)-6-(3-(4-((5-methylthiazol-2-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
58.	(E)-2-morpholino-N-(5-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)pyridin-2-yl)acetamide;

Comp. No	Compound Name
59.	(E)-2-(1H-imidazol-1-yl)-N-(5-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)pyridin-2-yl)acetamide;
60.	(E)-N-(5-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)pyridin-2-yl)-2-(1H-1,2,3-triazol-1-yl)acetamide;
61.	(E)-N-(3-(morpholinomethyl)-5-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)pyridin-2-yl)acetamide;
62.	(E)-6-(3-(4-benzyl-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
63.	(E)-6-(3-oxo-3-(4-(pyridin-4-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
64.	(E)-6-(3-(4-(4-fluorobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
65.	(E)-6-(3-(4-(3-fluorobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
66.	(E)-6-(3-(4-(2-fluorobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
67.	(E)-6-(3-(4-(3-chlorobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
68.	(E)-6-(3-(4-(4-chlorobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
69.	(E)-6-(3-oxo-3-(4-(4-(trifluoromethyl)benzyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
70.	(E)-6-(3-(4-(4-methylbenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-

Comp. No	Compound Name
	1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
71.	(E)-6-(3-(4-(3-methylbenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
72.	(E)-6-(3-(4-(2-methylbenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
73.	(E)-4-((1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)methyl)benzonitrile;
74.	(E)-3-((1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)methyl)benzonitrile;
75.	(E)-2-((1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)methyl)benzonitrile;
76.	(E)-6-(3-oxo-3-(4-(4-(trifluoromethoxy)benzyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
77.	(E)-6-(3-oxo-3-(4-(3-(trifluoromethoxy)benzyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
78.	(E)-6-(3-oxo-3-(4-(2-(trifluoromethoxy)benzyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
79.	(E)-6-(3-(4-(2-nitrobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
80.	(E)-6-(3-(4-(3-nitrobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
81.	(E)-6-(3-(4-(3-aminobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

Comp. No	Compound Name
82.	(E)-6-(3-(4-(2-methoxybenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
83.	(E)-6-(3-(4-(4-fluoro-2-methylbenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
84.	(E)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
85.	(E)-6-(3-(4-((5-nitrothiophen-2-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
86.	(E)-6-(3-(4-((3-methylthiophen-2-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
87.	(E)-6-(3-(4-((3-chlorothiophen-2-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
88.	(E)-N-(5-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl) prop-1-en-1-yl)pyridin-2-yl)acetamide;
89.	(E)-2-morpholino-N-(5-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)pyridin-2-yl)acetamide;
90.	(E)-3-(2-morpholinoethyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydro pyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one;
91.	(E)-8-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]diazepin-4(5H)-one;
92.	(E)-7-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one trifluoro

Comp. No	Compound Name
	aceticacid;
93.	(E)-4-methyl-7-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;
94.	(E)-tert-butyl-2-oxo-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxylate;
95.	(E)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one trifluoro aceticacid;
96.	(E)-1'-acetyl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;
97.	(E)-6-(3-oxo-3-(4-(thiazol-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
98.	(E)-6-(3-(4-((1-methyl-1H-pyrazol-4-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
99.	(E)-6-(3-(4-((1H-imidazol-1-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
100.	(E)-6-(3-(4-((1H-pyrazol-1-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
101.	(E)-6-(3-(4-((1H-1,2,3-triazol-1-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
102.	(E)-6-(3-(4-((1H-1,2,4-triazol-1-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

Comp. No	Compound Name
103.	(E)-6-(3-oxo-3-(4-(pyrrolidin-1-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
104.	(E)-6-(3-(4-(morpholinomethyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
105.	(E)-6-(3-(4-((3-methylbenzofuran-2-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
106.	(E)-6-(3-oxo-3-(4-(phenylethynyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
107.	(E)-6-(3-oxo-3-(4-(phenoxymethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
108.	(E)-6-(3-(4-((2-fluorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
109.	(E)-6-(3-(4-((3-fluorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
110.	(E)-6-(3-(4-((4-fluorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
111.	(E)-6-(3-(4-((2-chlorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
112.	(E)-6-(3-(4-((3-chlorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
113.	(E)-6-(3-(4-((4-chlorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

Comp. No	Compound Name
114.	(E)-6-(3-(4-((2-methoxyphenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
115.	(E)-6-(3-(4-((4-methoxyphenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
116.	(E)-6-(3-oxo-3-(4-((4-(trifluoromethoxy)phenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
117.	(E)-6-(3-(4-((2-methoxy-4-methylphenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
118.	(E)-6-(3-(4-((2-fluoro-4-nitrophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
119.	(E)-6-(3-(4-((4-ethyl-5-fluoro-2-methoxyphenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
120.	(E)-6-(3-oxo-3-(4-phenethyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
121.	(E)-6-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
122.	(E)-6-(3-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
123.	(E)-6-(3-(6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
124.	(E)-6-(3-(6-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

Comp. No	Compound Name
125.	6-((E)-3-oxo-3-(6-((E)-3-oxo-3-(pyrrolidin-1-yl)prop-1-en-1-yl)-3,4-dihydroisoquinolin-2(1H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
126.	6-((2-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl)thio)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
127.	(E)-6-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-3-(2-morpholinoethyl)-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one;
128.	(E)-tert-butyl 6-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-2-oxo-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxylate;
129.	(E)-6-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one trifluoro acetic acid;
130.	(E)-7-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;
131.	(E)-7-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-4-methyl-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;
132.	(E)-7-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-4-(2-morpholinoethyl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;
133.	(E)-1-(5-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)pyridin-2-yl)azetidin-2-one;
134.	(E)-N-(5-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)pyridin-2-yl)-2-morpholinoacetamide;
135.	(E)-N-(5-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)pyridin-2-yl)-2-(1H-imidazol-1-yl)acetamide;

Comp. No	Compound Name
136.	(E)-N-(5-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)pyridin-2-yl)-2-(1H-1,2,3-triazol-1-yl)acetamide;
137.	(E)-tert-butyl2-oxo-7-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-2,3-dihydro-1H-pyrido[2,3-e][1,4]diazepine-4(5H)-carboxylate;
138.	(E)-1'-(2-hydroxyacetyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;
139.	(E)-2-oxo-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxamide;
140.	(E)-1'-(3-methylbutanoyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydro pyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;
141.	(E)-1'-butyryl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;
142.	(E)-1'-(3,3-dimethylbutanoyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;
143.	(E)-8-(3-oxo-3-(4-(thiazol-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]diazepin-4(5H)-one;
144.	(E)-1'-(3-hydroxypropyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydro pyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;

Comp. No	Compound Name
145.	(E)-6-(3-oxo-3-(4-(thiazol-5-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;
146.	(E)-1'-methyl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;
147.	(E)-3-(2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)ethyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one;
148.	(E)-3-(2-(6-azaspiro[2.5]octan-6-yl)ethyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one;
149.	(E)-7-(3-oxo-3-(4-(thiazol-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;
150.	(E)-tert-butyl2-(2-(2-oxo-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1,2-dihydropyrido[2,3-d]pyrimidin-3(4H)-yl)ethyl)-2,7-diazaspiro[3.5]nonane-7-carboxylate; and
151.	(E)-3-(2-(2,7-diazaspiro[3.5]nonan-2-yl)ethyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one 2,2,2-trifluoroacetate;

or a pharmaceutically acceptable salt thereof.

14. A compound selected from the group consisting of

(E)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-7-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one trifluoro aceticacid;

(E)-1'-acetyl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;

(E)-6-(3-oxo-3-(4-(thiazol-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-1'-(3-methylbutanoyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydro pyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;

(E)-1'-butyryl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl) prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;

(E)-1'-(3-hydroxypropyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydro pyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;

(E)-6-(3-oxo-3-(4-(thiazol-5-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-1'-methyl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one; and

(E)-3-(2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)ethyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one;

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of formula (I) according to any of claim 1 to 14, their pharmaceutically acceptable derivatives, salts, solvates, tautomers, hydrates or individual isomers and mixtures of isomers thereof or respective N-oxide, in admixture with at least one pharmaceutically acceptable carrier or excipient including mixtures thereof in all ratios, for use as a medicament.

16. A method of treating bacterial infections which comprises administering to a subject in need thereof an effective amount of a compound according to any of claim 1 to 14.

17. A method for inhibiting FabI which comprises administering to a subject in need thereof an effective amount of a compound according to any of claim 1 to 14.


18. A compound according to any of claim 1 to 14, for use in the treatment of bacterial infections in animals including humans.

19. Use of a compound according to any of claim 1 to 14 in the manufacture of a medicament for use in the treatment of bacterial infections in animals including humans.

Claims:

1. A compound of formula (I):

(I)



or a pharmaceutically acceptable salts and stereoisomer's thereof;

wherein;

R_1 is selected from an optionally substituted alkyl, amino, cycloalkyl, aryl, heterocyclyl, heteroaryl, heterocyclylalkyl or heteroarylalkyl;

R_2 is hydrogen; or

R_1 and R_2 may be taken together with the atoms to which they are attached to form an optionally substituted 4-7 membered ring containing 0-3 additional hetero atoms independently selected from N, O and S in any stable combination;

R_3 is selected from hydrogen, carboxy, optionally substituted alkyl or heterocyclylalkyl; or

R_1 and R_3 may be taken together with the carbon atoms to which they are attached to form an optionally substituted 6-8 membered ring containing 0-3 additional hetero atoms independently selected from N, O and S in any stable combination; wherein the optional substituent, at each occurrence, is independently selected from one or more R_6;

L is a linker selected from $-CH_2-CH_2-$, -CH=CH- or $-CH_2-S-$;

R_4 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted amino, optionally substituted aryl, $B(OH)_2$, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heterocyclylalkyl, wherein the optional substituent, in each occurrence, is independently selected from one or more R_7;

R_5 is hydrogen; or

R_4 and R_5 may be taken together with the carbon atoms to which they are attached to form an optionally substituted 5-8 membered ring optionally containing 0-4 hetero atoms independently selected from N, O and S in any stable combination; wherein the optional substituent, at each

occurrence, is independently selected from alkoxy, halo, hydroxyl, an optionally substituted alkyl or an optionally substituted alkenyl;

R_6 is independently selected from optionally substituted alkyl, optionally substituted heterocyclylalkyl, $-COOR_8$ or two of the R_6 groups on the same atom combined together to form an optionally substituted spiro condensed 3-8 membered ring containing 0-3 hetero atoms independently selected from N, O and S;

wherein the optional substituent is independently selected from one or more R_8, $-(CH_2)_{1-3}OR_8$, $-COOR_8$, $-COR_8$, $-COCH_2OR_8$, $-CONR_8R_8$, $-NR_8R_8$ or an optionally substituted heterocyclyl;

R_7 is independently selected from cyano, nitro, halogen, $-OR_8$, $-NR_8R_8$, $-COOR_8$, $-CONR_8R_8$, $-NR_8COR_8$, haloalkyl, haloalkoxy, $-NHC(=NR_9)NHR_9$, $-(CH_2)_{1-3}OR_8$, $-C(=NOH)NH_2$ or optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryloxy, cyanoalkyl, cyanoalkoxy, cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl or optionally substituted heterocyclylalkyl;

R_8 at each occurrence is independently selected from hydrogen or optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, $-CH_2C(=NOH)NH_2$ or two of the R_8 groups on the same atom can be taken together with the atom to which they are attached to form an optionally substituted 3-8 membered ring containing 0-3 hetero atoms independently selected from N, O and S in any stable combination;

wherein the optional substituent is independently selected from $-COOC_1$-C_4alkyl, halogen, hydroxy, cyano, alkyl, alkoxy, nitro or haloalkoxy;

R_9 at each occurrence is independently selected from hydrogen or $-COOC_1$-C_4alkyl.

2. The compound of claim 1, wherein linker L is -CH=CH-.

3. The compound of claim 1, wherein R_1 is C_1-C_4alkyl or heterocyclylalkyl.

4. The compound of claim 1, wherein R_1 and R_3 can be taken together with the carbon atoms to which they are attached to form a 6-membered ring optionally substituted with one or more R_6.

5. The compound of claim 1, wherein R_1 and R_3 can be taken together with the carbon atoms to which they are attached to form a 7-membered ring containing one additional N atom and optionally substituted with one or more R_6.

6. The compound of claim 4, wherein R_6 is alkyl, heterocyclylalkyl or $-COOR_8$ wherein R_8 is C_{1-4} alkyl.

7. The compound of claim 5, wherein R_6 is alkyl, heterocyclylalkyl or $-COOR_8$ wherein R_8 is C_{1-4} alkyl.

8. The compound of claim 4, wherein two of the R_6 groups on the same atom combined together to form an optionally substituted spiro condensed 3-8 membered ring containing 0-3 hetero atoms independently selected from N, O and S; wherein the optional substituent is independently selected from alkyl, $-(CH_2)_{1-3}OR_8$, $-COOR_8$, $-COR_8$, $-COCH_2OR_8$, $-CONR_8R_8$, $-NR_8R_8$ or an optionally substituted heterocyclyl.


9. The compound of claim 5, wherein two of the R_6 groups on the same atom combined together to form an optionally substituted spiro condensed 3-8 membered ring containing 0-3 hetero atoms independently selected from N, O and S;

wherein the optional substituent is independently selected from alkyl, $-(CH_2)_{1-3}OR_8$, $-COOR_8$, $-COR_8$, $-COCH_2OR_8$, $-CONR_8R_8$, $-NR_8R_8$ or an optionally substituted heterocyclyl.

10. The compound of claim 1, wherein R_4 is aryl, arylalkyl, heteroaryl, or heteroarylalkyl which may be optionally substituted with R_7.

11. The compound of claim 1 wherein the compound of formula (I) is a compound of Formula (IA)


(IA)



wherein L, R_4 and R_5 are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 wherein the compound of formula (I) is a compound of Formula (IB)


(IB)



wherein R_{10} is selected from optionally substituted alkyl, $-(CH_2)_{1-3}OR_8$, $-COR_8$, $-COCH_2OR_8$ or $-CONR_8R_8$; and L, R_4, R_5 and R_8 are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 wherein the compound of formula (I) is a compound of Formula (IC)

(IC)




wherein R_{11} is selected from hydrogen, optionally substituted alkyl, heterocyclylalkyl or $-COOR_8$; and L, R_4, R_5 and R_8 are as defined in claim 1;

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 wherein the compound of formula (I) is a compound of Formula (ID)

(ID)



wherein L, R_4 and R_5 are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

15. A compound selected from the group consisting of

(E)-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)boronic acid;

(E)-6-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3-methylbenzofuran-2-yl)-5,6-dihydropyridin-1(2H)-yl)-3-oxop- rop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(5,6-dihydro-[4,4'-bipyridin]-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(5,6'-dihydro-[3,4'-bipyridin]-1'(2'H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(pyrimidin-2-yl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(pyrimidin-5-yl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(4-fluorophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(4-hydroxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3-hydroxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(2-hydroxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(4-methoxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3-methoxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(2-methoxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(4-(trifluoromethoxy)phenyl)-5,6-dihydropyridin-1(2H)-y- l)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(p-tolyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-3-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile;

(E)-4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile;

(Z)-N'-hydroxy-4-(1-((E)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzimidamide;

(E)-6-(3-(4-(4-nitrophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(4-aminophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-N-(4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)acetamide;

(E)-6-(3-(4-(3-nitrophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3-aminophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-N-(3-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)acetamide;

(E)-ethyl-4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloy- l)-1,2,3,6-tetrahydropyridin-4-yl)benzoate;

(E)-4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2- ,3,6-tetrahydropyridin-4-yl)benzoic acid;

(E)-4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2- ,3,6-tetrahydropyridin-4-yl)benzamide;

(E)-di-tert-butoxycarbonyl-1-(4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-napht- hyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)guanidine;

(E)-1-(4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)guanidine trifluoro aceticacid;

(E)-1-(3-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)guanidine;

(E)-2-(4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)acetonitrile;

(Z)-N'-hydroxy-2-(4-(1-((E)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)acetimidamide;

(E)-4-((4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)methyl)benzonitrile;

(E)-4-((4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzyl)oxy)benzonitrile;

(E)-6-(3-(4-(3-(morpholinomethyl)phenyl)-5,6-dihydropyridin-1(2H)-yl)-3-o- xoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3,5-dihydroxyphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3,4-dichlorophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(2-methyl-3-nitrophenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxopr- op-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3-amino-2-methylphenyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxopr- op-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-N-(2-methyl-3-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)a- cryloyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)acetamide;

(E)-6-(3-(4-(6-methoxynaphthalen-2-yl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo- prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(thiophen-2-yl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(thiazol-2-yl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(1-methyl-1H-imidazol-2-yl)-5,6-dihydropyridin-1(2H)-yl)-3-ox- oprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(1-methyl-1H-pyrazol-4-yl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo- prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-2-(4-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzyl)isoindoline-1,3-dione;

(E)-2-(3-(1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)benzyl)isoindoline-1,3-dione;

6-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)propyl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

6-((2-oxo-2-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)ethyl)thio)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-tert-butyl 2-oxo-6-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-2,- 4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxylate;

(E)-6-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one trifluoro aceticacid;

(E)-3-(2-morpholinoethyl)-6-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-y- l)prop-1-en-1-yl)-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one;

(E)-7-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one trifluoro aceticacid;

(E)-4-methyl-7-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;

(E)-4-(2-morpholinoethyl)-7-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-y- l)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;

(E)-6-(3-(4-((5-methylthiazol-2-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-2-morpholino-N-(5-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)pyridin-2-yl)acetamide;

(E)-2-(1H-imidazol-1-yl)-N-(5-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)pyridin-2-yl)acetamide;

(E)-N-(5-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)py- ridin-2-yl)-2-(1H-1,2,3-triazol-1-yl)acetamide;

(E)-N-(3-(morpholinomethyl)-5-(3-oxo-3-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)pyridin-2-yl) acetamide;

(E)-6-(3-(4-benzyl-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(pyridin-4-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(4-fluorobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3-fluorobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(2-fluorobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3-chlorobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(4-chlorobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(4-(trifluoromethyl)benzyl)-5,6-dihydropyridin-1(2H)-yl-)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(4-methylbenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3-methylbenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(2-methylbenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-4-((1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)methyl)benzonitrile;

(E)-3-((1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)methyl)benzonitrile;

(E)-2-((1-(3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acryloyl)-1,2,3,6-tetrahydropyridin-4-yl)methyl)benzonitrile;

(E)-6-(3-oxo-3-(4-(4-(trifluoromethoxy)benzyl)-5,6-dihydropyridin-1(2H)-y- l)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(3-(trifluoromethoxy)benzyl)-5,6-dihydropyridin-1(2H)-y- l)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(2-(trifluoromethoxy)benzyl)-5,6-dihydropyridin-1(2H)-y- l)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(2-nitrobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3-nitrobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(3-aminobenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(2-methoxybenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(4-fluoro-2-methylbenzyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((5-nitrothiophen-2-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((3-methylthiophen-2-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((3-chlorothiophen-2-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-N-(5-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)pr-op-1-en-1-yl)pyridin-2-yl)acetamide;

(E)-2-morpholino-N-(5-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridi- n-1(2H)-yl)prop-1-en-1-yl)pyridin-2-yl)acetamide;

(E)-3-(2-morpholinoethyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydro- pyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one;

(E)-8-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)pr- op-1-en-1-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]diazepin-4(5H)-one;

(E)-7-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one trifluoro aceticacid;

(E)-4-methyl-7-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;

(E)-tert-butyl-2-oxo-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyrid- in-1(2H)-yl)prop-1-en-1-yl)-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-p- iperidine]-1'-carboxylate;

(E)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one trifluoro aceticacid;

(E)-1'-acetyl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H-)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;

(E)-6-(3-oxo-3-(4-(thiazol-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((1-methyl-1H-pyrazol-4-yl)methyl)-5,6-dihydropyridin-1(2H)-y- l)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((1H-imidazol-1-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((1H-pyrazol-1-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((1H-1,2,3-triazol-1-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((1H-1,2,4-triazol-1-yl)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(pyrrolidin-1-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)pro- p-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-(morpholinomethyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((3-methylbenzofuran-2-yl)methyl)-5,6-dihydropyridin-1(2H)-yl-)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(phenylethynyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-(phenoxymethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((2-fluorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxop- rop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((3-fluorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((4-fluorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((2-chlorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((3-chlorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((4-chlorophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((2-methoxyphenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo- prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((4-methoxyphenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl)-3-oxo- prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-((4-(trifluoromethoxy)phenoxy)methyl)-5,6-dihydropyridi- n-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((2-methoxy-4-methylphenoxy)methyl)-5,6-dihydropyridin-1(2H)- yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((2-fluoro-4-nitrophenoxy)methyl)-5,6-dihydropyridin-1(2H)-yl-)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(4-((4-ethyl-5-fluoro-2-methoxyphenoxy)methyl)-5,6-dihydropyridi- n-1(2H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-oxo-3-(4-phenethyl-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3- ,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihyd- ro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-3- ,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(6-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

6-((E)-3-oxo-3-(6-((E)-3-oxo-3-(pyrrolidin-1-yl)prop-1-en-1-yl)-3,4-dihyd- roisoquinolin-2(1H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

6-((2-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl)thio)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-6-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-3-(2-morp-holinoethyl)-3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one;

(E)-tert-butyl 6-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-2-oxo-2,4-dih- ydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxylate;

(E)-6-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-1H-spiro[-[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one trifluoro acetic acid;

(E)-7-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-4,5-dihyd- ro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;

(E)-7-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-4-methyl- 4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;

(E)-7-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)-4-(2-morp- holinoethyl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;

(E)-1-(5-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)pyridin-2-yl)azetidin-2-one;

(E)-N-(5-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)pyridin-2-yl)-2-morpholinoacetamide;

(E)-N-(5-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)pyridin-2-yl)-2-(1H-imidazol-1-yl)acetamide;

(E)-N-(5-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxoprop-1-en-1-yl)pyridin-2-yl)-2-(1H-1,2,3-triazol-1-yl)acetamide;

(E)-tert-butyl2-oxo-7-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridi- n-1(2H)-yl)prop-1-en-1-yl)-2,3-dihydro-1H-pyrido[2,3-e][1,4]diazepine-4(5H-)-carboxylate;

(E)-1'-(2-hydroxyacetyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydrop- yridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin-]-2(4H)-one;

(E)-2-oxo-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl-)prop-1-en-1-yl)-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxamide;

(E)-1'-(3-methylbutanoyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydro pyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperid- in]-2(4H)-one;

(E)-1'-butyryl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(- 2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;

(E)-1'-(3,3-dimethylbutanoyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6- dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-p- iperidin]-2(4H)-one;

(E)-8-(3-oxo-3-(4-(thiazol-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]diazepin-4(5H)-one;

(E)-1'-(3-hydroxypropyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydro pyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperid- in]-2(4H)-one;

(E)-6-(3-oxo-3-(4-(thiazol-5-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-1'-methyl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H-)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;

(E)-3-(2-(2-oxo-7-azaspiro[3,5]nonan-7-yl)ethyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydropyrido- [2,3-d]pyrimidin-2(1H)-one;

(E)-3-(2-(6-azaspiro[2,5]octan-6-yl)ethyl)-6-(3-oxo-3-(4-(thiophen-2-ylme- thyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydropyrido[2,3-d]- pyrimidin-2(1H)-one;

(E)-7-(3-oxo-3-(4-(thiazol-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one;

(E)-tert-butyl2-(2-(2-oxo-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydro- pyridin-1(2H)-yl)prop-1-en-1-yl)-1,2-dihydropyrido[2,3-d]pyrimidin-3(4H)-y- l)ethyl)-2,7-diazaspiro[3.5]nonane-7-carboxylate; and

(E)-3-(2-(2,7-diazaspiro[3.5]nonan-2-yl)ethyl)-6-(3-oxo-3-(4-(thiophen-2- yl methyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydropyrido[2- ,3-d]pyrimidin-2(1H)-one 2,2,2-trifluoroacetate; or a pharmaceutically acceptable salt thereof.

16. A compound selected from the group consisting of

(E)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-7-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one trifluoro acetic acid;

(E)-1'-acetyl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H-)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;

(E)-6-(3-oxo-3-(4-(thiazol-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-1'-(3-methylbutanoyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydro pyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperid- in]-2(4H)-one;

(E)-1'-butyryl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2- H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one;

(E)-1'-(3-hydroxypropyl)-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydr- o pyridin-1(2H)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperi- din]-2(4H)-one;

(E)-6-(3-oxo-3-(4-(thiazol-5-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydro-1,8-naphthyridin-2(1H)-one;

(E)-1'-methyl-6-(3-oxo-3-(4-(thiophen-2-ylmethyl)-5,6-dihydropyridin-1(2H-)-yl)prop-1-en-1-yl)-1H-spiro[[1,8]naphthyridine-3,4'-piperidin]-2(4H)-one; and

(E)-3-(2-(2-oxo-7-azaspiro[3,5]nonan-7-yl)ethyl)-6-(3-oxo-3-(4-(thio- phen-2-ylmethyl)-5,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)-3,4-dihydropy- rido[2,3-d]pyrimidin-2(1H)-one;

or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of formula (I) according to claim 1, their pharmaceutically acceptable salts and stereoisomers thereof, with at least one pharmaceutically acceptable carrier, diluent or excipient including mixtures thereof in all ratios.